Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.

WATCH THE VIDEO HERE!